PFG Advisors 13F: New $1.8M Stake in XBI

PFG Advisors has initiated a new stake in the State Street SPDR S&P Biotech ETF (XBI) by acquiring 11,480 shares valued at approximately $1.81 million in a filing on October 16, 2026. This new position indicates the fund's interest in the biotech sector, which is represented by the ETF's focus on the S&P Biotechnology Select Industry Index.

What Changed in PFG Advisors' Position

PFG Advisors opened a new position, taking 11,480 shares of the ETF. This new stake reflects the firm's strategy to invest in biotech, aligning with its investment goals.

State Street SPDR S&P Biotech ETF Stock Down 1.5%

The ETF recently traded around $144.50, which is 8.6% below its 50-day moving average of $158.17. It is also 14.9% below its 52-week high of $169.89. This positioning suggests it may be a strategic time for new investors considering its recent performance.

Recent Earnings

There are no recent earnings data available for the State Street SPDR S&P Biotech ETF at this time.

Dividend

The ETF offers a dividend yield of about 0.35%, indicating a small but consistent return for investors.

About State Street SPDR S&P Biotech ETF

The State Street SPDR S&P Biotech ETF aims to track the performance of the S&P Biotechnology Select Industry Index. This index focuses on companies in the biotech segment, making the ETF a vehicle for investors looking to gain exposure to this specialized sector.

Bottom Line

Investors should keep an eye on PFG Advisors' future filings and the ETF's performance in upcoming months. The recent stake by PFG Advisors reflects ongoing interest in biotech investments, which can be influenced by market developments and sector performance. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.